loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Ustekinumab reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ustekinumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 14Stelara

    02 2Stelara

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 7,707

    2019 Revenue in Millions : 6,361

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    Japan
    arrow
    Luxepack
    Not Confirmed

    Mitsubishi Tanabe

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 265

    2019 Revenue in Millions : 230

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 9,134

    2020 Revenue in Millions : 7,707

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    Japan
    arrow
    Luxepack
    Not Confirmed

    Mitsubishi Tanabe

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 406

    2020 Revenue in Millions : 262

    Growth (%) : 67

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 9,723

    2021 Revenue in Millions : 9,134

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    Japan
    arrow
    Luxepack
    Not Confirmed

    Mitsubishi Tanabe

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 500

    2021 Revenue in Millions : 435

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 10,858

    2022 Revenue in Millions : 9,723

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    Japan
    arrow
    Luxepack
    Not Confirmed

    Mitsubishi Tanabe

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 439

    2022 Revenue in Millions : 500

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication :

    Currency : USD

    2014 Revenue in Millions : 37.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Stelara

    Ustekinumab

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Stelara

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Johnson & Johnson

    Ustekinumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2015 Revenue in Millions : 2,072

    2014 Revenue in Millions : 2,474

    Growth (%) : 19%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF